Skip to main content

Table 2 Summary of recent pivotal clinical trials in advanced soft tissue sarcomas

From: Spotlight on landmark oncology trials: the latest evidence and novel trial designs

Tumour type, phase [reference] Line of therapy Arms (experimental vs. control) Response rate Clinical benefit rate Median PFS (months, P value) Median OS (months, P value)
Non-adipocytic soft tissue sarcoma, phase 3, n = 369 [19] Second or later (after anthracycline) Pazopanib 800 mg/m2 vs. placebo 6% vs. 0% 73% vs. 38% 4.6 vs. 1.6 (P < 0.0001) 12.5 vs. 10.7 (P = 0.25)
Liposarcoma and leiomyosarcoma, phase 3, n = 518 [20] Second or later (after anthracycline) Trabectedine 1.5 mg/m2 vs. dacarbazine 1000 mg/m2 10% vs. 7% 61% vs. 42% 4.2 vs. 1.5 (P < 0.001) 12.4 vs. 12.9 (P = 0.37)
Liposarcoma and leiomyosarcoma, phase 3, n = 452 [21] Third or later (after anthracycline) Eribulin mesylate 1.4 mg/m2 vs. dacarbazine 850–1200 mg/m2 5% vs. 4% 57% vs. 52% 2.6 vs. 2.6 (P = 0.23) 13.5 vs. 11.5 (P = 0.01)
Soft tissue sarcoma, phase 2, n = 133 [22] First line Olaratumab 15 mg/kg plus doxorubicin 75 mg/m2 vs. doxorubicin alone 75 mg/m2 18.2% vs. 11.9% 77.3% vs. 62.7% 6.6 vs. 4.1 (P = 0.06) 26.5 vs. 14.7 (P = 0.0003)
  1. OS overall survival; PFS progression-free survival